10-K: Sharps Technology Pivots to Solana, Reports $282.5M Loss

Sharps Technology, Inc. shifts its core strategy to a Solana-focused digital asset treasury, reporting a substantial net loss of $282.5 million for the fiscal year ended December 31, 2025.

Summary

• The company has transitioned from primarily designing and manufacturing medical syringes to a medical device sales and distribution enterprise, alongside a new digital asset treasury strategy.
• A digital asset treasury strategy was adopted on August 23, 2025, focusing on accumulating Solana (SOL), which now constitutes the principal holding in its treasury reserve.
• A Private Investment in Public Equity (PIPE) offering closed on August 28, 2025, raising approximately $400 million, which was primarily used to purchase over 2,000,000 SOL.
• The company reported a significant net loss of $282.5 million for the fiscal year ended December 31, 2025, compared to a net loss of $9.3 million in 2024.
• Key drivers for the 2025 net loss included $107.5 million in stock compensation charges, $152.9 million in unrealized losses on digital assets, and asset impairments.
• As of December 31, 2025, the fair value of digital assets held was $250.1 million, with an average cost basis of approximately $198 per SOL, declining to a market value of $124 per SOL.
• Net staking revenue from SOL holdings amounted to $6.8 million in 2025, with approximately 95% of SOL holdings staked.
• A share repurchase program of up to $100 million was approved on October 2, 2025, leading to the repurchase of 867,678 shares for $1.57 million (excluding fees) between January and March 2026.
• Outstanding litigation was settled on October 6, 2025, resulting in the spinoff of the Hungarian subsidiary, Safegard Medical Kft.
• The company underwent reverse stock splits in April 2025 (1-for-300) and October 2024 (1-for-22).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly speculative and risky pivot. While the company successfully raised significant capital and generated staking revenue, the massive net loss, driven by unrealized digital asset losses and substantial related-party compensation, indicates severe financial underperformance and significant execution risk in its new strategy.

Positives

• Successfully raised approximately $400 million through a Private Investment in Public Equity (PIPE) offering.
• Established a digital asset treasury strategy with over 2,000,000 Solana (SOL) acquired, diversifying its asset base.
• Generated $6.8 million in net staking revenue from its SOL holdings in 2025, indicating a productive use of digital assets.
• Approved a $100 million share repurchase program, demonstrating a commitment to returning value to shareholders, with initial repurchases already executed.
• Resolved outstanding litigation and spun off its Hungarian subsidiary, streamlining operations and reducing legal overhead.

Negatives

• Reported a substantial net loss of $282.5 million for 2025, a significant increase from $9.3 million in 2024.
• Incurred $152.9 million in unrealized losses on digital assets due to a decline in SOL's market value from an average cost basis of $198 to $124 per SOL.
• Recorded $101.3 million in warrant issuance to a related party, contributing to high stock compensation charges of $107.5 million.
• Experienced a realized loss on derivatives of $4.98 million in 2025.
• Paid $3.4 million in consulting fees to related parties, raising concerns about potential conflicts of interest.
• Discontinued research and development and manufacturing activities for medical devices, indicating a shift away from its original core business model.
• Accumulated deficit grew to $316.9 million as of December 31, 2025, highlighting a history of losses.

Risks

• The company has a limited operating history on which to judge its performance and assess prospects for future success, particularly with its new digital asset strategy.
• The further development and acceptance of Solana and other cryptocurrency networks are subject to a variety of difficult-to-evaluate factors, and a slowdown could adversely affect the investment.
• Digital asset trading platforms are relatively new, largely unregulated, and may not comply with existing regulations, exposing the company to market manipulation, fraud, and security risks.
• The shift towards a SOL-focused strategy requires substantial changes in day-to-day operations and exposes the company to significant operational risks, including managing validator nodes and secure key management.
• Blockchain technologies are based on theoretical conjectures that may become incorrect due to technological advances, such as quantum computing, potentially undermining the Solana network.
• Conflicts of interest may arise with the related-party Consultant (Sol Edge Limited) and Strategic Advisor (Sol Markets), both controlled by the Chief Investment Officer's brother, potentially affecting operations adversely.
• Security breaches or cyberattacks on the company or its third-party service providers could lead to a loss of some or all of its SOL holdings, materially affecting financial condition.
• The company's stock price may be volatile and fluctuate substantially, influenced by its SOL Treasury Policy and the highly volatile prices of SOL.
• Concentration in a single digital asset (SOL) exposes the company to unique liquidity risks, potentially preventing conversion of SOL into fiat currency during market stress.
• The staking program involves a temporary loss of transferability of staked SOL during deactivation or cooldown periods, limiting flexibility.
• Regulatory developments related to crypto assets and markets, including potential reclassification of SOL as a security, could adversely affect the business and lead to the company being deemed an investment company.
• The company relies on third-party custodians, trading platforms, and DeFi protocols, and any failure or malfeasance by these counterparties could result in total or partial loss of digital assets.
• The company does not independently maintain its own insurance coverage over digital asset holdings, relying on custodians' policies which may be insufficient.
• Use of DeFi protocols exposes the company to risks such as smart contract vulnerabilities, cyberattacks, and uncertain regulatory treatment.
• The company may not be able to raise additional capital on acceptable terms, compromising its ability to implement and sustain its Treasury Policy.
• The company's shares are subject to potential delisting if it does not maintain Nasdaq Capital Market listing requirements.
• Future securities issuances could result in significant dilution to stockholders and impair the market price of common stock.
• The company does not intend to pay dividends on its common stock for the foreseeable future, meaning investor returns depend solely on stock price appreciation.

Future Outlook

The company plans to expand its medical device distribution platform by partnering with third-party manufacturers. Its treasury and engineering teams will continue to analyze strategic acquisitions and investments globally, as well as develop digital products. Profit generation is anticipated primarily through potential price appreciation of SOL and protocol-native staking rewards. The company may explore stablecoin-denominated yield strategies as the GENIUS Act regulatory framework matures. It intends to stake up to 95% of its SOL holdings and may utilize derivatives for hedging and yield enhancement. Share repurchases are also a potential future action to create shareholder value.

Management Comments

• "We plan to expand its distribution platform by representing established third-party manufacturers of complementary and synergistic medical products serving a common customer base."
• "We have been and continue to prioritize long term growth of the Companys business, potentially using proceeds from the sale of SOL to fund our expansion plans described above."
• "We believe that these activities [treasury strategy], conducted within the prescribed governance and risk limits, support its objective of producing sustainable, risk-adjusted returns while maintaining a conservative operational posture."
• "We intend to stake up to 95% of our total SOL holdings, and will utilize the remaining unstaked SOL primarily for liquidity management, potential validator operations and as collateral for any margin loans or future lending agreements."
• "We believe Solana is advantaged by best-in-class technology and strong network effects that have attracted a large, growing, and vibrant ecosystem of users, developers, and decentralized applications."

Industry Context

StockSavvy.ai notes that Sharps Technology's pivot from medical devices to a Solana-focused digital asset treasury strategy is a significant departure from its original business model, reflecting a broader trend of companies exploring digital assets for treasury management and yield generation. This move positions the company within the rapidly evolving cryptocurrency and blockchain industry, particularly the Solana ecosystem, which is known for its high throughput and growing DeFi and dApp activity. The company's strategy to generate yield through staking and derivatives, while holding a significant portion of its treasury in SOL, aligns with some institutional approaches to digital asset exposure but also concentrates risk in a single, volatile asset class. The mention of the GENIUS Act highlights the increasing regulatory clarity for stablecoins, which could open new avenues for yield strategies, but the overall digital asset regulatory landscape remains uncertain and rapidly evolving.

Management Changes

Corporate Governance

Legal Proceedings

• On October 6, 2025, the company entered into a confidential settlement agreement and release with Barry Berler, Plastomold Industries Ltd, Plasto Design Solutions, Plasto Design Ltd., and Plasto Technology Group LLC, resolving all claims alleged in the Litigation.
• The settlement involved the transfer of certain assets and the assignment of all rights to Safegard Medical Kft (Hungarian subsidiary) to Plasto Technology.

Related Party Transactions

• Consulting services provided by Sol Edge Limited (controlled by James Zhang, brother of CIO Alice Zhang) amounted to $3,333,333 in 2025, with a remaining prepaid expense of $6,666,667 for the annual payment.
• Warrants to purchase 6,321,367 shares of common stock were issued to Sol Markets (Strategic Advisor, also controlled by James Zhang) with an FMV of $101,331,513 in 2025.
• Marketing fees of $100,000 were paid to Sol Markets in 2025.
• Alice Zhang's husband, Jason Hu, was a senior employee of Sol Edge Limited until recently.
• Accounts payable and accrued liabilities included $26,572 (2025) and $99,500 (2024) payable to officers and directors.
• Paul Danner (Principal Executive Officer, Interim Principal Financial Officer, and Chairman) purchased five shares of Series B Preferred Stock for $20.00 per share on July 15, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity issuances and warrant exercises, coupled with high volatility in share price due to SOL price fluctuations. No dividends are expected in the foreseeable future.
• Employees saw increased staffing for the Digital Asset Treasury build-out and severance paid to the former CEO. Stock options were granted to directors, executives, and other personnel.
• Customers in the medical device segment may experience impacts from the discontinuation of R&D and manufacturing activities, potentially affecting future product availability or innovation.
• Creditors benefited from the repayment of a margin loan, improving the company's short-term liquidity position.
• Regulatory bodies will likely increase scrutiny due to the company's digital asset strategy and related-party transactions, requiring strict compliance with evolving digital asset regulations.

Next Steps

• Expand distribution platform by representing established third-party medical product manufacturers.
• Treasury strategy and engineering teams to continue analyzing strategic acquisitions/investments globally and develop digital products.
• Potentially use proceeds from SOL sales to fund expansion plans.
• Explore allocating a portion of treasury to stablecoin-denominated lending, liquidity provision, or other yield-generating activities under the GENIUS Act framework.
• Continue to stake up to 95% of total SOL holdings.
• Monitor Solana governance proposals and protocol development activity for potential slashing implementation.
• Potentially repurchase shares of common stock under the 2025 Repurchase Program.
• Onboard additional qualified custodians to mitigate SOL treasury risk.

Key Dates

Recommendation

The company's dramatic pivot to a highly speculative digital asset treasury strategy, coupled with a massive net loss driven by unrealized losses on its primary asset (SOL) and substantial related-party compensation, indicates extreme risk and poor financial performance. The inherent volatility and regulatory uncertainty of cryptocurrencies, combined with significant conflicts of interest in related-party transactions, make this a high-risk investment with a negative outlook. The discontinuation of its original medical device manufacturing business further removes a tangible, albeit struggling, revenue stream.

Keywords

Solana, SOL, Digital Assets, Cryptocurrency, Treasury Strategy, Staking, SEC Filing, 10-K, Financial Report, Share Repurchase, Corporate Governance, Risk Management, Nasdaq, Warrants, Equity Offering, Related Party Transactions, Medical Devices